About UsManagement Team
Board of Directors
Advisory Board
 
 

Management Team:

 
 

 
Linda Black, DVM, PhD
Co-Founder & Chief Executive Officer

Dr. Black has 20 years of experience in human and animal healthcare, focusing on regenerative medicine and cellular therapy development since 2007. She led the clinical development strategy to add new indications for autologous adipose-derived stem cell therapy for dogs and horses with the first and largest veterinary regenerative medicine company. As VP of Product Development, Dr. Black led the development team for allogeneic FDA-regulated cell therapy products to treat osteoarthritis in dogs. She has consulted for numerous human and veterinary regenerative medicine and cell therapy companies. Dr. Black received a DVM from the University of Wisconsin-Madison and a PhD in Cell and Molecular Biology from the University of Pennsylvania , School of Medicine.

 

  Steven Stice, PhD
Co-Founder & Chairman of the Scientific Advisory Board

Dr. Stice is a University of Georgia Research Alliance Eminent Scholar and the Director of the University of Georgia Regenerative Bioscience Center. He has an extensive background in animal health technology and stem cell applications along with an entrepreneurial record of successful companies generated from IP he developed. Dr. Stice was a co-founder and former Chief Scientific Officer at Advanced Cell Technology, Inc., a stem cell company with a market cap of $150 million. His current research activities are varied including working with the Bill and Melinda Gates Foundation to develop disease resistant livestock and developing stem cell therapies for Stroke and Parkinson’s. He has published and lectured internationally on stem cells throughout his career, with research findings highlighted in the NY Times, USA Today, Time Magazine, CNN, CBS, NBC and ABC News broadcasts.

 

  Scott Burger, MD
Head of Manufacturing & Regulatory

Dr. Burger has over 20 years of experience developing novel cell-, gene-, and tissue-based products and related technology. He is former VP for R&D at Merix Bioscience, a cellular immunotherapy company, and served as medical director of the University of Minnesota Cell Therapy Clinical Laboratory, where he was responsible for development and GMP manufacturing. Dr. Burger founded Advanced Cell & Gene Therapy, a consulting firm specializing in development and commercialization of cell and gene therapy, and tissue-engineered products, providing expert guidance on regulatory affairs, GMP/GTP manufacturing, and strategic issues. Dr. Burger chairs the Global Regulatory Affairs steering committee of the International Society for Cellular Therapy (ISCT), is a member of the ISCT commercialization committee, and has served on the USP Cell, Gene and Tissue Therapies Expert Committee. He is Chairman of the Scientific Advisory Board (SAB) of HemaCare Corporation, and has authored more than 100 scientific publications and presentations, Dr. Burger is a graduate of the University of Pennsylvania School of Medicine and completed training in clinical pathology and transfusion medicine at Washington University in St. Louis.

 

  April Treadwell, MBA
VP of Operations & Finance

Ms. Treadwell brings over 10 years of experience in accounting and financial management with a focus on stem cell therapy applications. She has worked closely on compliance with international licensing agreements and maintained financial records for government contracts. Her expertise includes a unique approach to operational procedures, streamlining, and cash flow management.

 


  Susan Hand
Director of Quality Assurance

Ms. Hand brings over 20 years of experience in Quality Systems and Compliance Management and has focused exclusively in the field of stem cell therapy for the past decade.  Her expertise includes the design, implementation, and management of Quality Assurance Programs and FDA regulation.